Articles
Protecting intellectual property in collaborative environments
As products become more complex, firms need to collaborate more with each other and also with their clients to be able to deliver new more capable systems
[ + ]How Iatia changed its fortunes by changing its business model
Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model. [ + ]
OPINION: View from the summit
Southern Cross Equities biotech analyst Stuart Roberts was behind the recent DNA, Devices and Dealers conference in Sydney. Here, he explains his passion for hanging out with biotech's true believers. [ + ]
A super way to invest in biotech
What are the odds that Australians' precious nest eggs be used to invest in something as risky as biotech? Well guess what -- it's already happening, and governments face pressure to free up more superannuation funds, writes Ruth Beran. [ + ]
Riding the biotech rollercoaster
Expat Kiwi Simon Moroney knows all too well the vagaries of the share market through his listed German biotech company, MorphoSys, writes Fiona Rotherham. [ + ]
What is the Science Industry Action Agenda?
The Australian science industry has grown in the last few years. While the progress being made by Australian industries is impressive, there are still many ways in which to improve efficiency and marketability on a global market
[ + ]Commercial reality for Australian-developed leukaemia diagnostic test
University of Sydney spin-out company Medsaic has developed a proprietary technology, DotScan, which can be used to diagnose haematological malignancies, solid tissue tumours and autoimmune diseases
[ + ]Biotech incubator seeks members
A new biotechnology incubator facility due to open in Queensland by the end of this year is calling for companies seeking mentoring and support. [ + ]
INTERVIEW: Turbocharging for growth
Cochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers. [ + ]
Opinion: Why we're backing off from biotech
Dump the drugs? No -- but dump the stigma of 'biotech' and look for proper recognition from the investment community, writes CogState CEO Peter Bick. [ + ]
How harmful is half-baked hiring?
You may be strapped for time, but a poorly-chosen new recruit could set you back even further, writes Jeremy Wurm. [ + ]
Why it's never too early for ethics
If your brain disengages when you read the word 'ethics', perhaps you'd better switch it on again, writes Iain Scott -- there's a lot you haven't heard on the subject. [ + ]
A solution to the elemental characterisation of materials
In an outcome recalling one of Australia's greatest scientific achievements, researchers from the CRC for Clean Power from Lignite (CRC CPL) have designed and commercialised a revolutionary instrument
[ + ]NMR method rapidly solves genomic structures
A University at Buffalo scientist created a stir in 2003 when he announced a much faster, more precise and far less expensive method of obtaining nuclear magnetic resonance (NMR) data to map a protein's atomic structure
[ + ]Orchestrating serendipity
Ann Uldridge explains the reasoning behind a new group for women in the biotechnology industry. [ + ]
